{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:15:32Z","timestamp":1783422932744,"version":"3.54.6"},"reference-count":142,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA171979"],"award-info":[{"award-number":["R01-CA171979"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01-CA174439"],"award-info":[{"award-number":["P01-CA174439"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA177423"],"award-info":[{"award-number":["R01-CA177423"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA016520"],"award-info":[{"award-number":["P30-CA016520"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The Epstein-Barr virus (EBV) is the first human tumor virus identified that can transform quiescent B lymphocytes into lymphoblastoid cell lines (LCLs) in vitro. EBV can establish asymptomatic life-long persistence and is associated with multiple human malignancies, including non-Hodgkin lymphoma and Hodgkin lymphoma, as well as infectious mononucleosis. Although EBV-associated lymphomagenesis has been investigated for over 50 years, viral-mediated transformation is not completely understood, and the development of EBV-specific therapeutic strategies to treat the associated cancers is still a major challenge. However, the rapid development of several novel therapies offers exciting possibilities to target EBV-induced lymphomas. This review highlights targeted therapies with potential for treating EBV-associated lymphomas, including small molecule inhibitors, immunotherapy, cell therapy, preventative and therapeutic vaccines, and other potent approaches, which are novel strategies for controlling, preventing, and treating these viral-induced malignances.<\/jats:p>","DOI":"10.3390\/cancers12092565","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T22:58:01Z","timestamp":1599778681000},"page":"2565","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7296-8772","authenticated-orcid":false,"given":"Yonggang","family":"Pei","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, and Microbiology, Tumor Virology Program, Abramson Comprehensive Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josiah H. Y.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, and Microbiology, Tumor Virology Program, Abramson Comprehensive Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erle S.","family":"Robertson","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, and Microbiology, Tumor Virology Program, Abramson Comprehensive Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis","volume":"8","author":"Georges","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.chom.2014.02.011","article-title":"Human viral oncogenesis: A cancer hallmarks analysis","volume":"15","author":"Mesri","year":"2014","journal-title":"Cell Host Microbe"},{"key":"ref_4","first-page":"263","article-title":"Kaposi sarcoma-associated herpesvirus and other viruses in human lymphomagenesis","volume":"312","author":"Cesarman","year":"2007","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev.pathol.1.110304.100209","article-title":"Spectrum of Epstein-Barr virus-associated diseases","volume":"1","author":"Kutok","year":"2006","journal-title":"Annu. Rev. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1093\/emboj\/16.20.6131","article-title":"Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule","volume":"16","author":"Gires","year":"1997","journal-title":"EMBO J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/35095584","article-title":"Epstein-Barr virus: Exploiting the immune system","volume":"1","year":"2001","journal-title":"Nat. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/sj.onc.1209023","article-title":"LMP1 signaling and activation of NF-kappaB in LMP1 transgenic mice","volume":"25","author":"Thornburg","year":"2006","journal-title":"Oncogene"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"12592","DOI":"10.1073\/pnas.94.23.12592","article-title":"The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB","volume":"94","author":"Izumi","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10838","DOI":"10.1128\/JVI.74.22.10838-10845.2000","article-title":"Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase\/Akt pathway","volume":"74","author":"Swart","year":"2000","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1128\/JVI.78.4.1697-1705.2004","article-title":"Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase\/Akt pathway","volume":"78","author":"Fukuda","year":"2004","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s42003-020-0996-z","article-title":"Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies target the PI3K\u03b3 isoform","volume":"3","author":"Pei","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"re4","DOI":"10.1126\/stke.3352006re4","article-title":"Notch and Wnt signaling: Mimicry and manipulation by gamma herpesviruses","volume":"2006","author":"Hayward","year":"2006","journal-title":"Sci. STKE"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1073\/pnas.0408381102","article-title":"Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt\u2019s lymphoma","volume":"102","author":"Cerimele","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1002\/anie.200901917","article-title":"The search for infectious causes of human cancers: Where and why (Nobel lecture)","volume":"48","author":"Hausen","year":"2009","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41579-018-0064-6","article-title":"Molecular mechanisms of viral oncogenesis in humans","volume":"16","author":"Krump","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/sj.onc.1208618","article-title":"Cyclins and cdks in development and cancer: A perspective","volume":"24","author":"Deshpande","year":"2005","journal-title":"Oncogene"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nrc3090","article-title":"Cyclin D as a therapeutic target in cancer","volume":"11","author":"Musgrove","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Saha, A., Halder, S., Upadhyay, S.K., Lu, J., Kumar, P., Murakami, M., Cai, Q., and Robertson, E.S. (2011). Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1001275"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e00663-18","DOI":"10.1128\/JVI.00663-18","article-title":"Epstein-Barr Virus nuclear antigen 3C facilitates cell proliferation by regulating Cyclin D2","volume":"92","author":"Pei","year":"2018","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4049\/jimmunol.155.3.1047","article-title":"Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated growth inhibition in EBV-positive B cells","volume":"155","author":"Arvanitakis","year":"1995","journal-title":"J. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"E3473","DOI":"10.1073\/pnas.1202637109","article-title":"Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells","volume":"109","author":"Tsang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1101\/gad.1256504","article-title":"Living with or without cyclins and cyclin-dependent kinases","volume":"18","author":"Sherr","year":"2004","journal-title":"Genes Dev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.devcel.2008.01.013","article-title":"CDK inhibitors: Cell cycle regulators and beyond","volume":"14","author":"Besson","year":"2008","journal-title":"Dev. Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1128\/JVI.78.4.1981-1991.2004","article-title":"Epstein-Barr virus nuclear antigen 3C regulates cyclin A\/p27 complexes and enhances cyclin A-dependent kinase activity","volume":"78","author":"Knight","year":"2004","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"12857","DOI":"10.1128\/JVI.78.23.12857-12867.2004","article-title":"A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells","volume":"78","author":"Knight","year":"2004","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1002\/j.1460-2075.1996.tb00635.x","article-title":"The Epstein-Barr virus bZIP transcription factor Zta causes G0\/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors","volume":"15","author":"Cayrol","year":"1996","journal-title":"EMBO J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.cell.2016.05.080","article-title":"A BH3 mimetic for killing cancer cells","volume":"165","author":"Green","year":"2016","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/0092-8674(91)90007-L","article-title":"Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death","volume":"65","author":"Henderson","year":"1991","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Pei, Y., Banerjee, S., Jha, H.C., Sun, Z., and Robertson, E.S. (2017). An essential EBV latent antigen 3C binds Bcl6 for targeted degradation and cell proliferation. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006500"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41564-020-0724-y","article-title":"DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression","volume":"5","author":"Guo","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Banerjee, S., Lu, J., Cai, Q., Saha, A., Jha, H.C., Dzeng, R.K., and Robertson, E.S. (2013). The EBV latent antigen 3C inhibits apoptosis through targeted regulation of interferon regulatory factors 4 and 8. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003314"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e22509","DOI":"10.7554\/eLife.22509","article-title":"Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection","volume":"6","author":"Price","year":"2017","journal-title":"eLife"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1073\/pnas.0901036106","article-title":"The Epstein-Barr virus Bcl-2 homolog, BHRF1, blocks apoptosis by binding to a limited amount of Bim","volume":"106","author":"Desbien","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.cell.2014.04.034","article-title":"A computationally designed inhibitor of an Epstein-Barr viral Bcl-2 protein induces apoptosis in infected cells","volume":"157","author":"Procko","year":"2014","journal-title":"Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"29987","DOI":"10.1074\/jbc.M303977200","article-title":"Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP\/USP7","volume":"278","author":"Holowaty","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.molcel.2005.02.029","article-title":"Structure of the p53 binding domain of HAUSP\/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization","volume":"18","author":"Saridakis","year":"2005","journal-title":"Mol. Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"12616","DOI":"10.1073\/pnas.94.23.12616","article-title":"Inhibition of ubiquitin\/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1","volume":"94","author":"Levitskaya","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"18562","DOI":"10.1073\/pnas.0503886102","article-title":"Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase","volume":"102","author":"Knight","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1128\/JVI.02279-10","article-title":"EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5","volume":"85","author":"Saha","year":"2011","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/1541-7786.MCR-18-0924","article-title":"Targeted therapy for EBV-associated B-cell neoplasms","volume":"17","author":"Ganguly","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1182\/blood-2011-01-332379","article-title":"Bortezomib induction of C\/EBPbeta mediates Epstein-Barr virus lytic activation in Burkitt lymphoma","volume":"117","author":"Shirley","year":"2011","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/nm.1864","article-title":"Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors","volume":"14","author":"Fu","year":"2008","journal-title":"Nat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1074\/jbc.M507305200","article-title":"Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells","volume":"281","author":"Lu","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e00378-18","DOI":"10.1128\/mSphereDirect.00378-18","article-title":"Spleen Tyrosine Kinase Inhibitor TAK-659 prevents splenomegaly and tumor development in a murine model of Epstein-Barr Virus-associated Lymphoma","volume":"3","author":"Cen","year":"2018","journal-title":"mSphere"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"11269","DOI":"10.1021\/acs.chemrev.7b00077","article-title":"Small-molecule modulation of protein homeostasis","volume":"117","author":"Burslem","year":"2017","journal-title":"Chem. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: An emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/487308a","article-title":"Chemical biology: Greasy tags for protein removal","volume":"487","author":"Neklesa","year":"2012","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Li, N., Thompson, S., Schultz, D.C., Zhu, W., Jiang, H., Luo, C., and Lieberman, P.M. (2010). Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010126"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/1087057110379154","article-title":"Development of a high-throughput screen for inhibitors of Epstein-Barr virus EBNA1","volume":"15","author":"Thompson","year":"2010","journal-title":"J. Biomol. Screen."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0092-8674(95)90232-5","article-title":"Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein EBNA 1","volume":"83","author":"Bochkarev","year":"1995","journal-title":"Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0092-8674(00)81056-9","article-title":"Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA","volume":"84","author":"Bochkarev","year":"1996","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1128\/jvi.71.3.1766-1775.1997","article-title":"Dominant-negative inhibitors of EBNA-1 of Epstein-Barr virus","volume":"71","author":"Kirchmaier","year":"1997","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"eaau5612","DOI":"10.1126\/scitranslmed.aau5612","article-title":"Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth","volume":"11","author":"Messick","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1086\/515290","article-title":"Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype","volume":"177","author":"Chodosh","year":"1998","journal-title":"J. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0140-6736(00)02879-8","article-title":"Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system","volume":"356","author":"Slobod","year":"2000","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1093\/emboj\/19.12.3080","article-title":"The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators","volume":"19","author":"Feederle","year":"2000","journal-title":"EMBO J."},{"key":"ref_60","first-page":"237","article-title":"Epstein-Barr virus lytic cycle reactivation","volume":"391","author":"McKenzie","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1093\/nar\/28.20.3918","article-title":"Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation","volume":"28","author":"Chang","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/272373a0","article-title":"Persisting oncogenic herpesvirus induced by the tumour promotor TPA","volume":"272","author":"Hausen","year":"1978","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0042-6822(79)90455-0","article-title":"Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate","volume":"94","author":"Luka","year":"1979","journal-title":"Virology"},{"key":"ref_64","first-page":"5781","article-title":"Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: A potential method for treating EBV-positive malignancies","volume":"60","author":"Westphal","year":"2000","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1128\/jvi.67.6.3240-3245.1993","article-title":"Analysis of the BZLF1 promoter of Epstein-Barr virus: Identification of an anti-immunoglobulin response sequence","volume":"67","author":"Shimizu","year":"1993","journal-title":"J. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/276270a0","article-title":"Activation of latent Epstein-Barr virus by antibody to human IgM","volume":"276","author":"Tovey","year":"1978","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1021\/cb4006326","article-title":"Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr Virus","volume":"9","author":"Tikhmyanova","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00001622-200109000-00008","article-title":"Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies","volume":"13","author":"Faller","year":"2001","journal-title":"Curr. Opin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1128\/JVI.02487-09","article-title":"The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production","volume":"84","author":"Meng","year":"2010","journal-title":"J. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Van Diemen, F.R., Kruse, E.M., Hooykaas, M.J., Bruggeling, C.E., Schurch, A.C., van Ham, P.M., Imhof, S.M., Nijhuis, M., Wiertz, E.J., and Lebbink, R.J. (2016). CRISPR\/Cas9-mediated genome editing of herpesviruses limits productive and latent infections. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005701"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.molcel.2020.03.025","article-title":"MYC controls the Epstein-Barr virus lytic switch","volume":"78","author":"Guo","year":"2020","journal-title":"Mol. Cell."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"a014266","DOI":"10.1101\/cshperspect.a014266","article-title":"Therapeutic strategies to inhibit MYC","volume":"4","author":"McKeown","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ccell.2019.10.001","article-title":"Small-molecule MYC inhibitors suppress Tumor growth and enhance immunotherapy","volume":"36","author":"Han","year":"2019","journal-title":"Cancer cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"312ra176","DOI":"10.1126\/scitranslmed.aab1803","article-title":"Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma","volume":"7","author":"Carter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41375-018-0178-x","article-title":"Epstein\u2212Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas","volume":"33","author":"Anastasiadou","year":"2019","journal-title":"Leukemia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","article-title":"PD-L1 is upregulated by EBV-driven LMP1 through NF-\u03baB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma","volume":"9","author":"Bi","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.pathol.2018.08.011","article-title":"EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression","volume":"50","author":"Xue","year":"2018","journal-title":"Pathology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3324\/haematol.2016.141978","article-title":"Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: A clinical and pathological study in 82 patients","volume":"101","author":"Laurent","year":"2016","journal-title":"Haematologica"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13027-020-00292-w","article-title":"Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program","volume":"15","author":"Granai","year":"2020","journal-title":"Infect. Agents Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Quan, L., Chen, X., Liu, A., Zhang, Y., Guo, X., Yan, S., and Liu, Y. (2015). PD-1 blockade can restore functions of T-cells in Epstein-Barr virus-positive diffuse large B-cell lymphoma in vitro. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136476"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"611","DOI":"10.4143\/crt.2018.191","article-title":"Comparison of efficacy of pembrolizumab between Epstein-Barr viruspositive and negative relapsed or refractory non-hodgkin lymphomas","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Ma, S.-D., Xu, X., Jones, R., Delecluse, H.-J., Zumwalde, N.A., Sharma, A., Gumperz, J.E., and Kenney, S.C. (2016). PD-1\/CTLA-4 blockade inhibits Epstein-Barr virus-induced lymphoma growth in a cord blood humanized-mouse model. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005642"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12943-019-0977-3","article-title":"MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1\/PD-L1-mediated lymphoma cell interaction with CD8+T cells","volume":"18","author":"Zheng","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/2040620711412417","article-title":"Therapeutic options in post-transplant lymphoproliferative disorders","volume":"2","author":"Zimmermann","year":"2011","journal-title":"Ther. Adv. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/j.1600-6143.2007.01823.x","article-title":"Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation","volume":"7","author":"Comoli","year":"2007","journal-title":"Am. J. Transplant."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/ped.13336","article-title":"Pre-emptive rituximab for Epstein\u2013Barr virus reactivation after haplo-hematopoietic stem cell transplantation","volume":"59","author":"Kobayashi","year":"2017","journal-title":"Pediatr. Int."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1182\/blood.V99.12.4364","article-title":"Prevention of Epstein-Barr virus\u2013lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation","volume":"99","author":"Niesters","year":"2002","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1158\/1535-7163.MCT-05-0253","article-title":"Anti-CD70 antibodies: A potential treatment for EBV+ CD70-expressing lymphomas","volume":"4","author":"Israel","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","article-title":"Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation","volume":"330","author":"Papadopoulos","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm0596-551","article-title":"Long-term restoration of immunity against Epstein\u2013Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes","volume":"2","author":"Heslop","year":"1996","journal-title":"Nat. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Icheva","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CJI.0000000000000031","article-title":"T-cell therapy using a bank of EBV-specific cytotoxic T cells: Lessons from a phase I\/II feasibility and safety study","volume":"37","author":"Gallot","year":"2014","journal-title":"J. Immunother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/intimm\/dxh401","article-title":"T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFN\u03b3 production","volume":"18","author":"Schaft","year":"2006","journal-title":"Int. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/bjc.2017.475","article-title":"A novel Epstein\u2013Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy","volume":"118","author":"Cho","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e22590","DOI":"10.4161\/onci.22590","article-title":"Human MHC class I-restricted high avidity CD4(+) T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo","volume":"2","author":"Xue","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"716926","DOI":"10.1155\/2011\/716926","article-title":"Evaluation of Epstein-Barr virus latent membrane protein 2 specific T-cell receptors driven by T-cell specific promoters using lentiviral vector","volume":"2011","author":"Yang","year":"2011","journal-title":"Clin. Dev. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.jcyt.2019.03.569","article-title":"CD19 chimeric antigen receptor (CAR) engineered epstein-barr virus (EBV) specific T cells\u2014An off-the-shelf, allogeneic CAR T-cell immunotherapy platform","volume":"21","author":"Shen","year":"2019","journal-title":"Cytotherapy"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"468","DOI":"10.7555\/JBR.28.20140066","article-title":"T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo","volume":"28","author":"Tang","year":"2014","journal-title":"J. Biomed. Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/318287a0","article-title":"Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine","volume":"318","author":"Epstein","year":"1985","journal-title":"Nature"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jmv.1890250209","article-title":"Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas","volume":"25","author":"Morgan","year":"1988","journal-title":"J. Med. Virol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/S0264-410X(98)00351-X","article-title":"The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines","volume":"17","author":"Wilson","year":"1999","journal-title":"Vaccine"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/jvi.43.2.730-736.1982","article-title":"Identification and isolation of the main component (gp350\u2013gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo","volume":"43","author":"Poodry","year":"1982","journal-title":"J. Virol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1073\/pnas.77.9.5307","article-title":"Monoclonal antibodies against the major glycoprotein (gp350\/220) of Epstein-Barr virus neutralize infectivity","volume":"77","author":"Geilinger","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1038\/cti.2014.27","article-title":"Epstein-barr virus vaccines","volume":"4","author":"Cohen","year":"2015","journal-title":"Clin. Transl. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0264-410X(98)00248-5","article-title":"Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine","volume":"17","author":"Jackman","year":"1999","journal-title":"Vaccine"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","article-title":"Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site","volume":"162","author":"Kanekiyo","year":"2015","journal-title":"Cell"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","article-title":"Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults","volume":"25","author":"Moutschen","year":"2007","journal-title":"Vaccine"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Weiss, E.R., Alter, G., Ogembo, J.G., Henderson, J.L., Tabak, B., Bakis, Y., Somasundaran, M., Garber, M., Selin, L., and Luzuriaga, K. (2017). High Epstein-Barr virus load and genomic diversity are associated with generation of gp350-Specific neutralizing antibodies following acute infectious mononucleosis. J. Virol., 91.","DOI":"10.1128\/JVI.01562-16"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","article-title":"Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein-Barr virus in B cells and epithelial cells","volume":"50","author":"Bu","year":"2019","journal-title":"Immunity"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.immuni.2018.03.026","article-title":"An antibody targeting the fusion machinery neutralizes dual-tropic infection and defines a site of vulnerability on Epstein-Barr virus","volume":"48","author":"Snijder","year":"2018","journal-title":"Immunity"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Mundo, L., Del Porro, L., Granai, M., Siciliano, M.C., Mancini, V., Santi, R., Marcar, L., Vrzalikova, K., Vergoni, F., and Di Stefano, G. (2020). Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: Expanding the landscape of EBV-related lymphomas. Mod. Pathol.","DOI":"10.1038\/s41379-020-0608-y"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"13105","DOI":"10.1128\/JVI.05598-11","article-title":"A virus-like particle-based Epstein-Barr virus vaccine","volume":"85","author":"Ruiss","year":"2011","journal-title":"J. Virol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1128\/JVI.02533-12","article-title":"An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA","volume":"87","author":"Pavlova","year":"2013","journal-title":"J. Virol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fonc.2019.00104","article-title":"Progress in EBV vaccines","volume":"9","author":"Mautner","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"14257","DOI":"10.1038\/ncomms14257","article-title":"Epstein-Barr virus particles induce centrosome amplification and chromosomal instability","volume":"8","author":"Shumilov","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Van Zyl, D.G., Tsai, M.H., Shumilov, A., Schneidt, V., Poirey, R., Schlehe, B., Fluhr, H., Mautner, J., and Delecluse, H.J. (2018). Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007464"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","article-title":"A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: A phase I trial in UK patients with EBV-positive cancer","volume":"20","author":"Taylor","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1128\/JVI.78.2.768-778.2004","article-title":"Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: Potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma","volume":"78","author":"Taylor","year":"2004","journal-title":"J. Virol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934","article-title":"Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin\u2019s disease","volume":"91","author":"Roskrow","year":"1998","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin lymphoma","volume":"122","author":"Kuppers","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","article-title":"The immunology of Epstein-Barr virus-induced disease","volume":"33","author":"Taylor","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"22791","DOI":"10.1038\/srep22791","article-title":"A generic screening platform for inhibitors of virus induced cell fusion using cellular electrical impedance","volume":"6","author":"Watterson","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-981-10-5765-6_5","article-title":"Current progress in EBV-associated B-Cell lymphomas","volume":"1018","author":"Pei","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S1470-2045(19)30164-0","article-title":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Jiang","year":"2019","journal-title":"Lancet. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41571-019-0224-2","article-title":"HDAC inhibitors tested in phase III trial","volume":"16","author":"Romero","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Eckschlager, T., Plch, J., Stiborova, M., and Hrabeta, J. (2017). Histone deacetylase inhibitors as anticancer drugs. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071414"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/9\/2565\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:08:11Z","timestamp":1760177291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/9\/2565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,9]]},"references-count":142,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["cancers12092565"],"URL":"https:\/\/doi.org\/10.3390\/cancers12092565","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,9]]}}}